- Prev close
- $83.02
- Day range
- $82.09 – $85.06
- Next earnings
- in 81 days
DexCom’s 2026-08-01 close jumped +12.0% after a session that opened at $79.88 and finished at $83.45, but the move sits against a market that rose only modestly and is better explained by stock-specific news flow and an earnings setup than by the tape alone.
DXCM
DEXCOM INC
As of Aug 2, 2026
62/100
Worth keeping an eye onHealth ScoreMove driver
DXCM rose +12.0% on 2026-08-01, while the S&P 500 rose +0.7% and the Nasdaq 100 rose +0.6%; that gap is too large to attribute to the broad market. No same-sector peer move was provided, so the clean read is stock-specific: the session was driven by company-level news and positioning around earnings, not by index strength. The intraday path also mattered: it opened at $79.88, traded to $84.7, and closed at $83.45, which looks like a strong advance that held most of its gains rather than a full fade.
Volatility check
This looks like elevated but not abnormal volatility for a name with beta 1.41, meaning it tends to move about 41% more than the market. The fundamentals are still solid — revenue growth is +16.1% YoY (TTM), the latest quarter is +15.1% YoY, EPS is +77.5% YoY (TTM), and margins are healthy at gross +63.4%, operating +21.4%, and net +19.3%. The valuation is not cheap at PE 34.6 and forward PE 26.1, with PEG 1.41; because EPS growth is positive, that PEG is meaningful and says investors are already paying for growth. So the +12.0% move is not explained by a deterioration in the business; it is a large but defensible swing in a richly rated growth stock, which amplifies moves in either direction.
Earnings setup
DexCom scheduled its second quarter 2026 earnings release for July 30, 2026 at 4:30 p.m. Eastern Time, but the actual consensus revenue/EPS expectations are not provided in the facts here, so I cannot state them precisely. The report will likely be judged on whether the +15.1% YoY latest-quarter revenue growth and +77.5% YoY EPS growth are holding up, whether operating margin stays near +21.4%, and whether management reaffirms the growth path after the Investor Day sentiment shift and the separate Class II recall of unauthorized G7 sensor lots. Prior earnings reaction history is not available in the facts, so I won’t infer a pattern from past prints.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track DXCM with WhyIHold
Get a plain-English explanation the next time DEXCOM INC makes a big move — so you know whether it's benign or worth your attention.